Drug intelligence / Profile preview

olmesartan + amlodipine

Development stage
Unknown
Lead developer
INNventa Pharm
Modality
Small Molecules
Administration
Oral
01

Overview

Duopresinn is a fixed-dose combination of olmesartan medoxomil and amlodipine besylate used for the treatment of hypertension. Olmesartan is an angiotensin II receptor antagonist (ARB) that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 receptor in vascular smooth muscle and the adrenal gland. Amlodipine is a dihydropyridine calcium channel blocker (CCB) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in peripheral arterial vasodilation and reduced peripheral vascular resistance. The combination of these two antihypertensive agents provides a synergistic effect in lowering blood pressure, often used when monotherapy is insufficient. It is distributed by INNventa Pharm as a branded generic product.

Brand names
DuopresinnAzorSevikar
Other names
olmesartan medoxomil + amlodipine besylateolmesartan/amlodipine
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on olmesartan + amlodipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on olmesartan + amlodipine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call